Ratings Just Issued on these 4 Healthtech Tickers

Tickers Inside If you cannot see this email properly, please click [here]( Dear Reader, Below is a list of 4 Buy Ratings made by some of the Top Analysts on Wall Street for stocks in the HealthTech Sector...Keep in mind, we are not recommending these companies, just reporting what Wall Street Analysts have issued. [For all the latest analyst ratings in the HealthTech Sector, click here](. --------------------------------------------------------------- Sponsorship [Where AI And Mining Intersect - Overlooked Connection Revealed]( [Learn how a young US company fits into the global AI race.]( --------------------------------------------------------------- [Rallybio, RLYB]( Mitchell Kapoor analyst at H.C. Wainwright reiterates coverage on [Rallybio (RLYB)](in the Healthcare sector with a Buy rating. TipRanks.com has Kapoor rated as a 0.2 star analyst with a 35% return on investment and a -13.1% success rate. Kapoor has set a price target of $17. [TipRanks.com]( reports that [Rallybio](currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $19.50. In addition, TradingView issued a Neutral rating for [RLYB]( over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. [Get the full story on other analysts covering RLYB by clicking here.]( --------------------------------------------------------------- [Madrigal Pharmaceuticals, MDGL]( Jonathan Wolleben analyst at JMP Securities reiterates coverage on [Madrigal Pharmaceuticals (MDGL)](in the Healthcare sector with a Buy rating. TipRanks.com has Wolleben rated as a 4.7 star analyst with a 45% return on investment and a 13.7% success rate. Wolleben has set a price target of $383. [TipRanks.com]( reports that [Madrigal Pharmaceuticals](currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $340.40. In addition, TradingView issued a Sell rating for [MDGL]( over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. [Get the full story on other analysts covering MDGL by clicking here.]( --------------------------------------------------------------- Sponsorship [Artificial Intelligence's Unquenchable Thirst For... Gold?!]( s right, a critical element in the modern-day AI revolution is none other than the oldest store of value in the world. The same properties that have made gold coveted for years now make it essential to the very technology powering our future. As AI and modern technology evolve so does demand from tech companies behind it. [See what this means for investors and reveal a young company racing to meet demand.]( --------------------------------------------------------------- [Arcturus Therapeutics, ARCT]( Ed Arce analyst at H.C. Wainwright reiterates coverage on [Arcturus Therapeutics (ARCT)](in the Healthcare sector with a Buy rating. [TipRanks.com]( has Arce rated as a 4.4 star analyst with a 41% return on investment and a 7.8% success rate. Arce has set a price target of $60. [TipRanks.com]( reports that [Arcturus Therapeutics](currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $73.20. In addition, TradingView issued a Strong buy rating for [ARCT]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. [Get the full story on other analysts covering ARCT by clicking here.]( --------------------------------------------------------------- [Biomea Fusion, BMEA]( Hartaj Singh analyst at Oppenheimer reiterates coverage on [Biomea Fusion (BMEA)](in the Healthcare sector with a Buy rating. [TipRanks.com]( has Singh rated as a 4.8 star analyst with a 47% return on investment and a 14.8% success rate. Singh has set a price target of $70. [TipRanks.com]( reports that [Biomea Fusion](currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $52.20. In addition, TradingView issued a buy rating for [BMEA]( over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. [Get the full story on other analysts covering BMEA by clicking here.]( --------------------------------------------------------------- Sponsorship [Turn market chaos into your #1 advantage]( t let market volatility erode your hard-earned savings. Our free gold guide shows you how to thrive in turbulent markets. So the more volatile markets become… or the dollar struggles… or inflation soars… the more secure your retirement becomes. It’s time to take charge of your wealth. Download our free guide to see how to turn your 401k into a gold IRA and protect your retirement today. [Download your free gold guide now]( --------------------------------------------------------------- Just a reminder, one resource you need to consider using [Tipranks.com]( where as a premium member you get access to all buy ratings, price targets and insider trading signals. [Click here for more on Tipranks.com.]( Another great tool for charting is [TradingView.com](, and for more news [Google Finance](, so you might want to check that out too. To you financial future! The Editor --------------------------------------------------------------- Sponsorship [Best way to buy gold today (not what you'd think)]( so many strange events happening across the economy (longest bear market for bonds since Civil War... unprecedented bank closures... and soaring prices) – it's no wonder the richest investors are loading up on gold. But what you might not realize is there's a much better way to profit from rising gold prices – without ever touching an ETF, mining stock, or even bullion. [Full details here.]( --------------------------------------------------------------- HealthTechMovers.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. [If you are not a human, click here.]( By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | NC | 28123 | United States | 8774119808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software